WO2008155035A3 - Oxazolidinone zur behandlung und prophylaxe von sepsis - Google Patents

Oxazolidinone zur behandlung und prophylaxe von sepsis Download PDF

Info

Publication number
WO2008155035A3
WO2008155035A3 PCT/EP2008/004565 EP2008004565W WO2008155035A3 WO 2008155035 A3 WO2008155035 A3 WO 2008155035A3 EP 2008004565 W EP2008004565 W EP 2008004565W WO 2008155035 A3 WO2008155035 A3 WO 2008155035A3
Authority
WO
WIPO (PCT)
Prior art keywords
sepsis
prophylaxis
treatment
septic
oxazolidinones
Prior art date
Application number
PCT/EP2008/004565
Other languages
English (en)
French (fr)
Other versions
WO2008155035A2 (de
Inventor
Georges Degenfeld
Elisabeth Perzborn
Claudia Hirth-Dietrich
Original Assignee
Bayer Schering Pharma Ag
Georges Degenfeld
Elisabeth Perzborn
Claudia Hirth-Dietrich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag, Georges Degenfeld, Elisabeth Perzborn, Claudia Hirth-Dietrich filed Critical Bayer Schering Pharma Ag
Publication of WO2008155035A2 publication Critical patent/WO2008155035A2/de
Publication of WO2008155035A3 publication Critical patent/WO2008155035A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Abstract

Die vorliegende Erfindung betrifft die Verwendung von Faktor Xa-Inhibitoren, insbesondere von Oxazolidinonen der Formel (I), zur Behandlung und/oder Prophylaxe von Sepsis, der disseminierten intravaskulären Gerinnung, des septischen Schocks, der septischen Organdysfunktion, des septischen Organversagens und/oder des ARDS sowie ihre Verwendung zur Herstellung von Arzneimitteln zur Behandlung und/oder Prophylaxe von Sepsis, der disseminierten intravaskulären Gerinnung, des Septischen Schocks, der septischen Organdysfunktion, des septischen Organversagens und/oder des ARDS.
PCT/EP2008/004565 2007-06-20 2008-06-07 Oxazolidinone zur behandlung und prophylaxe von sepsis WO2008155035A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007028318.2 2007-06-20
DE102007028318A DE102007028318A1 (de) 2007-06-20 2007-06-20 Oxazolidinone zur Behandlung und Prophylaxe von Sepsis

Publications (2)

Publication Number Publication Date
WO2008155035A2 WO2008155035A2 (de) 2008-12-24
WO2008155035A3 true WO2008155035A3 (de) 2009-05-07

Family

ID=40029255

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/004565 WO2008155035A2 (de) 2007-06-20 2008-06-07 Oxazolidinone zur behandlung und prophylaxe von sepsis

Country Status (2)

Country Link
DE (1) DE102007028318A1 (de)
WO (1) WO2008155035A2 (de)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030153610A1 (en) * 1999-12-24 2003-08-14 Alexander Straub Substituted oxazolidinones and their in the field of blood coagulation
WO2007039132A1 (de) * 2005-10-04 2007-04-12 Bayer Healthcare Ag Neue polymorphe form und die amorphe form von 5-chlor-n- ( { ( 5s ) -2-0x0-3-[4-( 3-oxo-4-morpholinyl) - phenyl] -1,3-oxazolidin-5-yl} -methyl) -2- thiophencarboxamid

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0610265B1 (de) 1991-11-01 1996-12-27 PHARMACIA & UPJOHN COMPANY Substituierte aryl- und heteroaryl-phenyloxazolidinone
SK283420B6 (sk) 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
EP0623615B1 (de) 1993-05-01 1999-06-30 MERCK PATENT GmbH Substituierte 1-Phenyl-oxazolidin-2-on Derivate, deren Herstellung und deren Verwendung als Adhäsionsrezeptor-Antagonisten
DE19524765A1 (de) 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE69631347T2 (de) 1995-09-15 2004-10-07 Upjohn Co Aminoaryl oxazolidinone n-oxide
GB9614238D0 (en) 1996-07-06 1996-09-04 Zeneca Ltd Chemical compounds
DE19755268A1 (de) 1997-12-12 1999-06-17 Merck Patent Gmbh Benzamidinderivate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030153610A1 (en) * 1999-12-24 2003-08-14 Alexander Straub Substituted oxazolidinones and their in the field of blood coagulation
WO2007039132A1 (de) * 2005-10-04 2007-04-12 Bayer Healthcare Ag Neue polymorphe form und die amorphe form von 5-chlor-n- ( { ( 5s ) -2-0x0-3-[4-( 3-oxo-4-morpholinyl) - phenyl] -1,3-oxazolidin-5-yl} -methyl) -2- thiophencarboxamid

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AKAHANE KAZUHISA ET AL: "Inhibition of factor Xa suppresses the expression of tissue factor in human monocytes and lipopolysaccharide-induced endotoxemia in rats", SURGERY (ST LOUIS), vol. 130, no. 5, November 2001 (2001-11-01), pages 809 - 818, XP002517042, ISSN: 0039-6060 *
BIEMOND BART J ET AL: "Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939) - an oral, direct factor Xa inhibitor", THROMBOSIS AND HAEMOSTASIS, STUTTGART, DE, vol. 97, no. 3, 1 March 2007 (2007-03-01), pages 471 - 477, XP009112785, ISSN: 0340-6245 *
FUJISHIMA YUKO ET AL: "The effect of danaparoid sodium (Danaparoid) on endotoxin-induced experimental disseminated intravascular coagulation (DIC) in rats", THROMBOSIS RESEARCH, vol. 91, no. 5, 1 September 1998 (1998-09-01), pages 221 - 227, XP002517041, ISSN: 0049-3848 *
HEINZELMANN MICHAEL ET AL: "Fondaparinux sodium lacks immunomodulatory effects of heparin.", AMERICAN JOURNAL OF SURGERY JAN 2004, vol. 187, no. 1, January 2004 (2004-01-01), pages 111 - 113, XP002517043, ISSN: 0002-9610 *
LEVI ET AL: "Plasma and plasma components in the management of disseminated intravascular coagulation", BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, BAILLIÈRE TINDALL, vol. 19, no. 1, 1 March 2006 (2006-03-01), pages 127 - 142, XP005219065, ISSN: 1521-6926 *

Also Published As

Publication number Publication date
DE102007028318A1 (de) 2008-12-24
WO2008155035A2 (de) 2008-12-24

Similar Documents

Publication Publication Date Title
WO2008011453A3 (en) SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1
WO2007126841A3 (en) Inhibition of alpha-synuclein toxicity
GB0625648D0 (en) Compounds
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
MA32272B1 (fr) Inhibiteurs de raf de pyrazole [3,4-b]pyridine
WO2007115620A3 (de) Neuartige cyclobutyl-verbindungen als kinase-inhibitoren
WO2011012746A3 (es) Compuestos inhibidores de apaf-1
TN2009000132A1 (en) Substituted dihydropyrazolones for treating cardiovascular and haematological diseases
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
UA106748C2 (uk) Похідні проліну як інгібітори катепсину
ECSP088358A (es) Tratamiento y profilaxis de microangiopatías
MY155418A (en) Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2008075068A3 (en) Acylaminopyrazoles as fgfr inhibitors
WO2008118711A3 (en) Method of inhibiting complement activation with human anti-factor c3 antibodies and use thereof
WO2008024497A3 (en) INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1
JP2009531281A5 (de)
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
WO2011044506A3 (en) Sulphone compounds for use in the treatment of obesity
WO2012046030A3 (en) Phosphodiesterase inhibitors
WO2007034279A3 (en) C3a antagonists and pharmaceutical compositions thereof
WO2010115751A3 (en) Oxadiazole derivatives
MX2007000224A (es) Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de nauseas y vomitos.
TW200730506A (en) Compounds and uses thereof
WO2007053495A3 (en) Compounds useful as antagonists of ccr2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08759101

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08759101

Country of ref document: EP

Kind code of ref document: A2